Life sciences companies should pay attention to an ongoing action in Delaware that could have implications for whether they can obtain (or be subjected to) U.S. discovery in international arbitration under 28 U.S.C. § 1782. Section 1782 is a powerful tool that permits litigants to obtain broad discovery in the United States for use in … Continue Reading
GT is pleased to have achieved a win on behalf of our client Teva Pharmaceuticals USA, Inc. In May 2018, a U.S. Federal District Court Judge from the Central District of California granted Teva’s motion to dismiss in its entirety without leave to amend. In April 2017, Plaintiffs commenced an action in California’s Riverside County … Continue Reading
According to a recent study conducted by Lex Machina, a leading US based legal analytics company, over the last eight and a half years Greenberg Traurig attorneys in the US have defended more commercial litigation cases than any other firm, and also filed more commercial disputes on behalf of plaintiffs. This achievement is enhanced by … Continue Reading
It is important for parties to a transaction who come from other less-litigious business environments to know that U.S. buyers and sellers operate in an environment where litigation is far more frequent, and even a single word can affect the outcome of a dispute. We believe that the example below (just one of many that … Continue Reading
